

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM742138

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
VYNE PHARMACEUTICALS INC.		01/12/2022	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Journey Medical Corporation		
<b>Street Address:</b>	9237 East Via De Ventura		
<b>Internal Address:</b>	Suite 105		
<b>City:</b>	Scottsdale		
<b>State/Country:</b>	ARIZONA		
<b>Postal Code:</b>	85258		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 9</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	88308081	MST	
<b>Serial Number:</b>	90892398	MST	
<b>Registration Number:</b>	6024563	AMZEEQ	
<b>Registration Number:</b>	6034820		
<b>Registration Number:</b>	6034819	AMZEEQ	
<b>Registration Number:</b>	6505432		
<b>Registration Number:</b>	6235231	ZILXI	
<b>Registration Number:</b>	6223436		
<b>Registration Number:</b>	6223434		
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2024084400		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2024084000		
<b>Email:</b>	docketing@finnegan.com		
<b>Correspondent Name:</b>	Christie Baty Hudgins		
<b>Address Line 1:</b>	901 New York Avenue NW		
<b>Address Line 2:</b>	Finnegan, Henderson, Farabow, Garrett &		

OP \$240.00 88308081

<b>Address Line 4:</b>	Washington, D.C. 20001
<b>ATTORNEY DOCKET NUMBER:</b>	15986.0999
<b>NAME OF SUBMITTER:</b>	Christie Baty Hudgins
<b>SIGNATURE:</b>	/Christie Baty Hudgins/
<b>DATE SIGNED:</b>	07/19/2022

**Total Attachments: 21**  
source=VYNE to Journey Medical - Worldwide Assignment#page1.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page2.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page3.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page4.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page5.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page6.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page7.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page8.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page9.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page10.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page11.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page12.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page13.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page14.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page15.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page16.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page17.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page18.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page19.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page20.tif  
source=VYNE to Journey Medical - Worldwide Assignment#page21.tif

**INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT**

This Intellectual Property Assignment Agreement (this “IP Assignment Agreement”), dated as of January 12, 2022, is entered into by and between VYNE Therapeutics Inc., a Delaware corporation (“VYNE Parent”), VYNE Pharmaceuticals Inc., a Delaware corporation and a wholly owned subsidiary of VYNE Parent (together with VYNE Parent, “Assignors”), and Journey Medical Corporation, a Delaware corporation (“Assignee”). Each Assignor and Buyer are referred to herein as a “Party” and, collectively, as the “Parties”. Capitalized terms used but not otherwise defined in this IP Assignment Agreement shall have the meanings ascribed to such terms in the Purchase Agreement (as defined below).

**RECITALS**

**WHEREAS**, VYNE Parent and Assignee are parties to that certain Asset Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant to which VYNE Parent has agreed that each Assignor will sell, assign, transfer, convey and deliver to Assignee, and Assignee has agreed to purchase, acquire and accept from each Assignor, all of such Assignor’s right, title and interest in, to and under the intellectual property set forth on Exhibit A, upon the terms contained in the Purchase Agreement; and

**WHEREAS**, the execution and delivery of this IP Assignment Agreement is contemplated by Sections 4.2(c) and 4.3(d) of the Purchase Agreement.

**NOW, THEREFORE**, in consideration of the mutual covenants herein contained and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

**AGREEMENT**

1. **Assignment.** Upon the terms and subject to the conditions of the Purchase Agreement (including Section 2.4 thereof), effective as of 12:01 am, Eastern Standard Time, on the Closing Date, each Assignor hereby irrevocably sells, assigns, transfers, conveys and delivers to Assignee and its permitted successors and assigns, and Assignee hereby irrevocably purchases, acquires and accepts from each Assignor, all right, title and interest of such Assignor in and to the following:

(a) (i) the patent applications or patents set forth on Exhibit A; (ii) any continuations, divisionals, or other patent applications that claim priority to any of the patent applications or patents in Exhibit A or that share a common claim of priority therewith; (iii) any patents issuing on any such patent applications (of either (i) or (ii)); (iv) any substitutions, reexaminations, reissues, registrations, corrections, additions, confirmation patents, revivals, and/or any similar modifications of any such patents in (iii) or listed in Exhibit A; (v) any extensions (including pediatric exclusivity, patent term extension, and supplementary patent certificate extensions) and/or or restorations of such patents (referenced in (iv)), including all rights in any such patent applications or patents (in (i)-(v)), in each case, whether domestic or foreign, including all rights of priority, rights to file and prosecute, and the like;

(b) the trademark registrations and applications listed on Exhibit A, together with the goodwill of the business connected with the use thereof, and symbolized thereby;

(c) the copyright registrations and applications for registration listed on Exhibit A;

(d) all rights in and to all income, royalties, damages and payments now or hereafter due or payable with respect to any or all of the foregoing; and

(e) all causes of action (whether in law or in equity) with respect to any of the foregoing, and the right to sue, counterclaim, and recover damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement of the rights assigned or to be assigned under this IP Assignment Agreement.

2. **Filing and Recordation.** The Parties hereby agree that Assignee shall promptly file and record this IP Assignment Agreement, or the equivalent of this IP Assignment Agreement to the extent required, with the appropriate governmental entities as necessary to record Assignee as the assignee and owner of the rights assigned or to be assigned under this IP Assignment Agreement. The Parties hereby authorize and request that the United States Patent and Trademark Office and the United States Copyright Office, and the corresponding entities or agencies in any applicable foreign jurisdictions, record Assignee as the assignee and owner of the entire right, title and interest in and to the intellectual property set forth on Exhibit A and issue the patents, and register the trademark registrations and copyright registrations, from any pending applications included in the intellectual property set forth on Exhibit A to Assignee upon issuance or registration.

3. **Further Assurances.** As and when reasonably requested by Assignee, each Assignor shall, and shall cause its respective Affiliates to, execute, acknowledge and deliver all reasonable further conveyances, notices, assumptions, releases and acquittances and instruments and take all such reasonable actions as may be necessary or appropriate to make effective the transactions contemplated hereby.

4. **Parties in Interest.** This IP Assignment Agreement shall be binding upon, shall inure to the benefit of, and shall be enforceable by the Parties, and their permitted successors and assigns. Except as noted above, this IP Assignment Agreement is for the sole benefit of the Persons specifically named in the preamble to this Agreement as Parties and their permitted successors and assigns, no Party hereto is acting as an agent for any other Person not named herein as a party hereto, and nothing in this IP Assignment Agreement or any other Transaction Agreements, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

5. **Governing Law.** This IP Assignment Agreement shall be governed by and enforced in accordance with the internal laws of the State of New York applicable to contracts made and performed in such State without giving effect to any Law or rule that would cause the Laws of any jurisdiction other than the State of New York to be applied.


6. **Conflicts.** The assignment made hereunder is in accordance with, and subject to the Purchase Agreement (including, without limitation, the representations, warranties, covenants and agreements contained therein). In the event of a conflict between the terms and conditions of this IP Assignment Agreement and the terms and conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement shall govern, supersede, and prevail. Notwithstanding anything to the contrary in this IP Assignment Agreement, nothing herein is intended to, nor shall it, extend, amplify, or otherwise alter the representations, warranties, covenants, and obligations of the Parties contained in the Purchase Agreement or the survival thereof.
7. **Counterparts.** This IP Assignment Agreement may be executed in counterparts, and signature pages may be delivered by facsimile, portable document format (PDF), DocuSign or any other electronic signature complying with the U.S. federal ESIGN Act of 2000 or the Electronic Signatures and Records Act of the State of New York, each of which shall be deemed an original, but all of which will be considered one and the same agreement and will become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party, it being understood that all Parties need not sign the same counterpart.
8. **Amendment; Waiver.** No provision of this IP Assignment Agreement may be amended, supplemented or modified except by a written instrument making specific reference hereto signed by all the Parties.

*[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]*


IN WITNESS WHEREOF, the Parties have caused this IP Assignment Agreement to be duly executed as of the date first written above.

**ASSIGNORS**

**VYNE THERAPEUTICS INC.**

By:   
Name: David Domzalski  
Title: Chief Executive Officer

**VYNE PHARMACEUTICALS INC.**

By:   
Name: David Domzalski  
Title: Chief Executive Officer

[Signature Page to the Intellectual Property Assignment Agreement]

**ASSIGNEE**

**JOURNEY MEDICAL CORPORATION**

By: Claude Maraoui  
Name: Claude Maraoui  
Title: President and Chief Executive Officer

**EXHIBIT A**

Set forth below is a list of patents and patent applications within Core Intellectual Property. VYNE Pharmaceuticals Inc. is the current owner of these patents and patent applications following an assignment from the Seller. Applications are being or will be made to each of the appropriate patent offices to reflect VYNE Pharmaceuticals Inc. as the owner.

**UNITED STATES**

<b>Serial No.</b>	<b>Publication No.</b>	<b>Patent No.</b>	<b>Title</b>	<b>Filing Date</b>	<b>Grant Date</b>
US 13/499,501	US 2013/0064777	US 8945516	Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Their Uses	1 Oct 10	3 Feb 15
US 14/850,655	US 2016/0101184	US 10238746	Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Gels And Their Uses	10 Sep 15	26 Mar 19
US 15/915,386	US 2018/0193469	US 10137200	Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Gels And Their Uses	8 March 18	27 Nov 18
US 16/235,986	US 2019/0134204	US 10946101	Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Gels And Their Uses	28 Dec 18	16 Mar 21
US 16/948,631	US 2021/0015927		Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Gels And Their Uses	26 Sept 20	
US 16/384,589	US 2019/0240239		Compositions, Gels And Foams With Rheology Modulators And Uses	15 Apr 19	
US 13/100,724	US 2011/0281827	US 8618081	Compositions, Gels And Foams With Rheology Modulators And Uses Thereof	4 May 11	31 Dec 13
US 14/078,746	US 2014/0066524	US 10265404	Compositions, Gels And Foams With Rheology Modulators And Uses Thereof	13 Nov 13	23 Apr 19
US 16/280,921	US 2019/0231886	US 10821187	Compositions, Gels And Foams With Rheology Modulators And Uses Thereof	20 Feb 19	03 Nov 20
US 16/387,381	US 2019/0275157	US 10835613	Compositions, Gels And Foams With Rheology Modulators And Uses Thereof	17 Apr 19	17 Nov 20
US 17/037,070	US 2021/0015928		Compositions, Gels And Foams With Rheology Modulators And Uses Thereof	Sept 28 20	
US 17/061,018	US 2021/0069335		Compositions, Gels And Foams With Rheology Modulators And Uses Thereof	Oct 1 20	
US 13/499,475	US 2013/0028850	US 8871184	Topical Tetracycline Compositions	1 Oct 10	28 Oct 14
US 14/327,040	US 2014/0328770	US 8865139	Topical Tetracycline Compositions	9 Jul 14	21 Oct 14
US 14/469,792	US 2015/0056149	US 8992896	Topical Tetracycline Compositions	27 Aug 14	31 Mar 15



Serial No.	Publication No.	Patent No.	Title	Filing Date	Grant Date
US 14/595,882	US 2015/0190409	US 9675700	Topical Tetracycline Compositions	13 Jan 15	13 July 17
US 15/591,733	US 2017/0340743	US 10213512	Topical Tetracycline Compositions	10 May 17	26 Feb 19
US 913,574/15	US 2018/0193468	US 10086080	Topical Tetracycline Compositions	6 March 18	2 Oct 18
US 16/235,964	US 2019/0134203	US 10322186	Topical Tetracycline Compositions	28 Dec 18	18 June 19
US 16/387,407	US 2019/0262456	US 10463742	Topical Tetracycline Compositions	17 Apr 19	05 Nov 19
US 16/578,252	US 2020/0016271	US 10610599	Topical Tetracycline Compositions	20 Sept 19	07 Apr 20
US 16/805,201	US 2020/0261586		Topical Tetracycline Compositions	28 Feb 20	
US 13/831,396	US 2013/0225536	US 9849142	Methods For Accelerated Return Of Skin Integrity And For The Treatment Of Impetigo	14 Mar 13	26 Dec 17
US 15/816,850	US 2018/0147218	US 10517882	Methods For Accelerated Return Of Skin Integrity And For The Treatment Of Impetigo	17 Nov 17	31 Dec 19
US 16/668,491	US 2020/0171057		Methods For Accelerated Return Of Skin Integrity And For The Treatment Of Impetigo	30 Oct 19	
US 17/025,156	US 2021/0077509		Compositions For The Improved Treatment Of Acne And Related Disorders	18 Sept 20	
US 15/699,692	US 2018/0064638	US 10398641	Compositions and Methods for Treating Rosacea and Acne	8 Sept 17	3 Sept 19
US 16/508,611	US 2020/0016068	US 10849847	Compositions and Methods for Treating Rosacea and Acne	11 Jul 19	1 Dec 20
US 17/075,217	US 2021/0205212		Compositions and Methods for Treating Rosacea and Acne	1 Oct 20	

**AUSTRALIA**

Serial No.	Patent No.	Title	Filing Date	Grant Date
AU 2010302350	AU 2010302350	Surfactant-Free Water-Free Foamable Foams And Gels And Their Uses	1 Oct 10	1 Oct 15
AU 2015224534	AU 2015224534	Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Gels And Their Uses	11 Sep 15	21 Sept 17

**CANADA**

Serial No.	Patent No.	Title	Filing Date	Grant Date
CA 2776366	CA 2776366	Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Gels And	1 Oct 10	18 July 17

		Their Uses		
CA 2776482		Compositions, Gels And Foams With Rheology Modulators And Uses Thereof	4 May 11	
CA 2776474	CA 2776474	Topical Tetracycline Compositions	1 Oct 10	10 Jan 21
CA 2867419		Use of Tetracycline Compositions for Wound Treatment and Skin Restoration	14 Mar 13	
CA 2978573		Compositions and Methods For Treating Rosacea	8 Sept 17	

**EUROPE**

Serial No.	Publication No.	Title	Filing Date	Grant Date
EP 10819992.8		Topical Tetracycline Compositions	1 Oct 10	
GB 1016546.2	GB 2474930	Topical Tetracycline Compositions	1 Oct 10	4 Jul 12

**ISRAEL**

Serial No.	Patent No.	Title	Filing Date	Grant Date
IL 218861	IL 218861	Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Their Uses	1 Oct 10	01 May 16
IL 218865	IL 218865	Topical Tetracycline Compositions	1 Oct 10	29 May 17

**INDIA**

Serial No.	Patent No.	Title	Filing Date	Grant Date
IN 882/KOLNP/2012		Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Gels And Their Uses	1 Oct 10	

**MEXICO**

Serial No.	Patent No.	Title	Filing Date	Grant Date
MX /a/2012/003985	MX 359879	Topical Tetracycline Compositions	1 Oct 10	12 Oct 18
MX /a/2017/011630	MX 377365	Compositions and Methods For Treating Rosacea	8 Sept 17	13 Nov 20
MX /a/2020/012139		Compositions and Methods For Treating Rosacea	12 Nov 20	

**SOUTH AFRICA**

Serial No.	Patent No.	Title	Filing Date	Grant Date
ZA 2012/03165	ZA 2012/03165	Surfactant-Free Water-Free Foamable Compositions, Breakable Foams And Gels And Their Uses	1 Oct 10	31 Jul 13

**TAIWAN**

Serial No.	Patent No.	Title	Filing Date	Grant Date
TW 109126107		Compositions and Methods and Uses Thereof	31 July 20	


**PCT**


Serial No.	Patent No.	Title	Filing Date <sup>1</sup>	Grant Date
PCT/US2020/044287		Compositions and Methods and Uses Thereof	30 July 20	

Set forth below is a list of trademarks:

**BRAZIL**

**Registered Trademarks**


Serial No.	Class	Registration No.	Registration Date
AMZEEQ	5	917719220	2/11/2020
Drop Logo	5	917643038	2/18/2020
			
ZILXI	5	920131670	5/11/2021
PEBBLE Logo	5	919972110	4/13/2021


			
MST	3	918007534	6/3/2020
MST	5	918007569	12/29/2020

**CANADA  
Registered Trademarks**

Mark	Class	Registration No.	Registration Date
AMZEEQ	5	1109379	7/29/2019

**Pending Applications**


Mark	Class	Application No.	Application Date
Drop Logo 	5	1993363	7/1/2019
ZILXI	5	2063339	7/13/2020
PEBBLE Logo	5	2041550	6/22/2020

			
MST	3 and 5	1998144	8/19/2019

**CHINA**

**Registered Trademarks**

Mark	Class	Registration No.	Registration Date
AMZEEQ	5	1485598	7/29/2019
Drop Logo	5	1494994	7/1/2019
ZILXI	5	1559645	7/13/2020
PEBBLE Logo	5	1542150	6/22/2020
PEBBLE Logo Color	5	47493954	3/14/2021







**EUROPEAN UNION**

**Registered Trademarks**



Mark	Class	Registration No.	Registration Date
AMZEEQ	5	1485598	7/29/2019
Drop Logo	5	1494994	7/1/2019
ZILXI	5	1559645	7/13/2020
PEBBLE Logo	5	1542150	6/22/2020
MST	3 and 5	1500011	8/19/2019

**ISRAEL  
Registered Trademarks**

Mark	Class	Registration No	Registration Date
AMZEEQ	5	320238	7/29/2019
Drop Logo 	5	321882	7/1/2019
Fingerprint design 	5	324766	2/6/2020
ZILXI	5	333350	7/13/2020
PEBBLE Logo 	5	329905	6/22/2020
MST	3 and 5	322753	8/19/2019
MOLECULE STABILIZING TECHNOLOGY (MST)	5	329186	7/1/2020

Mark	Class	Application No.	Application Date
MST Logo 	5	342610	8/18/2021

**MEXICO**  
**Registered Trademarks**

Mark	Class	Registration No.	Registration Date
AMZEEQ	5	1485598	7/29/2019
Drop Logo 	5	1494994	7/1/2019
MST	3	2301367	8/19/2019
PEBBLE Logo 	5	1542150	6/22/2020

**Pending Applications**



Mark	Class	Application No.	Application Date
ZILXI	5	1559645	7/13/2020
MST	5	2301368	8/19/2019

**RUSSIA**

**Registered Trademarks**

Mark	Class	Registration No.	Registration Date
AMZEEQ	5	1485598	7/29/2019
Drop Logo	5	1494994	7/1/2019
ZILXI		1559645	1/14/2020
PEBBLE Logo		1542150	6/22/2020



**Pending Applications**

Mark	Class	Application No.	Application Date
MOLECULE STABILIZING TECHNOLOGY (MST)	5	2020776924	12/31/2020

--	--	--	--

**TAIWAN**


**Registered Trademarks**

<b>Name</b>	<b>Class</b>	<b>Registration No.</b>	<b>Registration Date</b>
AMZEEQ	5	02150040	7/1/2021
Drop Logo	5	02150039	7/1/2021
			
ZILXI	5	02121042	2/16/2021
PEBBLE Logo	5	02121013	2/16/2021
			


**UNITED KINGDOM**





**Registered Trademarks**

<b>Name</b>	<b>Class</b>	<b>Registration No.</b>	<b>Registration Date</b>
AMZEEQ	5	1485598	7/29/2019
Drop Logo	5	1494994	7/1/2019


				
ZILXI	5	1559645	7/13/2020	
PEBBLE Logo	5	1542150	6/22/2020	
MST	3 and 5	1500011	8/19/2019	

**UNITED STATES  
 Registered Trademarks**

Mark	Class	Registration No.	Registration Date
AMZEEQ	5	6024563	3/31/2020
Drop Logo	5	6034820	4/14/2020
			
AMZEEQ and Drop Logo	5	6034819	4/14/2020

			
Fingerprint design 	5	6505432	10/5/2021
ZILXI	5	6235231	12/29/2020
PEBBLE Logo 	5	6223436	12/15/2020
PEBBLE Logo Color 	5	6223434	12/15/2020

**Pending Applications**

Mark	Class	Application No.	Application Date
MST	3 and 5	88308081	2/20/2019
MST Logo 	5	90892398	8/19/2021

Set forth below is a list of patents and patent applications within Non-Core Intellectual Property. VYNE Pharmaceuticals Inc. is the current owner of these patents and patent applications following an assignment from the Seller. Applications are being or will be made to each of the appropriate patent offices to reflect VYNE Pharmaceuticals Inc. as the owner.

**UNITED STATES**

Serial No.	Publication No.	Patent No.	Title	Filing Date	Grant Date
US 12/795,164	US 2010/0310476	US 8343945	Carriers, Formulations, Methods For Formulating Unstable Active Agents For External Application And Uses Thereof	7 Jun 10	1 Jan 13
US 13/732,024	US 2013/0189191	US 9161916	Carriers, Formulations, Methods For Formulating Unstable Active Agents For External Application And Uses Thereof	31 Dec 12	20 Oct 15
US 12/795,213	US 2011/0212033	US 8900553	Oil And Liquid Silicone Foamable Carriers And Formulations	7 Jun 10	02 Dec 14
US 14/504,942	US 2015/0118164	US 9549898	Oil And Liquid Silicone Foamable Carriers And Formulations	2 Oct 14	24 Jan 17
US 15/999,088	US 2019/0091149		Oil foamable carriers and formulations	17 Aug 18	
US 17/646,328			Oil foamable carriers and formulations	29 Dec 21	
US 13/123,213	US 2011/0268665	US 8518376	Oil-Based Foamable Carriers And Formulations	6 Oct 09	27 Aug 13
US 13/967,546	US 2014/0050673	US 9795564	Oil-Based Foamable Carriers And Formulations	15 Aug 13	24 Oct 17

Serial No.	Publication No.	Patent No.	Title	Filing Date	Grant Date
US 15/639,114	US 2017/0360705	US 9884017	Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	30 Jun 17	6 Feb 18
US 15/883,134	US 2018/0153804	US 10213384	Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	30 Jan 18	26 Feb 19
US 16/236,704	US 2019/0201339	US 10363216	Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	31 Dec 18	30 Jul 19
US 16/443,649	US 2019/0201339	US 10588858	Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	17 Jun 19	17 Mar 20
US 16/779,884	US 2020/ 0222320		Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	03 Feb 20	
US 15/401,743	US 2017/0216334	US 10092588	Foamable Compositions, Breakable Foams And Their Uses	9 Jan 17	9 Oct 18
US 16/108,799	US 2019/0054106		Foamable Compositions, Breakable Foams And Their Uses	22 Aug 18	
US 17/644,619			Foamable Compositions, Breakable Foams And Their Uses	16 Dec 21	
US 13/499,709	US 2013/0011342	US 10029013	Surfactant-Free, Water-Free, Foamable Compositions And Breakable Foams And Their Uses	1 Oct 10	24 July 18
US 16/019,623	US 2019/0000980	US 10967063	Surfactant-Free, Water-Free, Foamable Compositions And Breakable Foams And Their Uses	27 June 18	06 Apr 21
US 17/066,752			Surfactant-Free, Water-Free, Foamable Compositions And Breakable Foams And Their Uses	9 Oct 20	
US 17/644,245			Tetracycline Management of EGFR Inhibitor Associated Dermatoses	14 Dec 21	
US 16/624,244			Stable Topical Tetracycline Compositions	18 Dec 19	

CANADA

Serial No.	Patent No.	Title	Filing Date	Grant Date
CA 2760186	CA 2760186	Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	28 Apr 10	29 Oct 19
CA 2776471	CA 2776471	Surfactant-Free, Water-Free, Foamable Compositions And Breakable Foams And Their Uses	1 Oct 10	12 Feb 19
CA 2995794		Tetracycline Management of EGFR Inhibitor Associated Dermatoses	19 Aug 16	
CA 3067308		Stable Topical Tetracycline Compositions	13 Dec 19	

ISRAEL

Serial No.	Patent No.	Title	Filing Date	Grant Date
IL 218866	IL 218866	Surfactant-Free, Water-Free, Foamable Compositions And Breakable Foams And Their Uses	1 Oct 10	29 May 18

MEXICO

Serial No.	Patent No.	Title	Filing Date	Grant Date
MX /a/2018/002067		Tetracycline Management of EFGR inhibitor associated Dermatoses	19 Aug 16	